Jérôme Galon, 2019 european inventor for Immunoscore®

On June 20th 2019, Jérôme Galon, scientist and cofounder of HalioDx, received the 2019 european inventor award in the research category for his innovative test Immunoscore®.

On June 20th 2019, Jérôme Galon, scientist and cofounder of HalioDx, received the 2019 european inventor award in the research category for his innovative test Immunoscore®. He was one of only 6 french researchers awarded  in this category since the creation of the european inventor award in 2006. He is also the first Inserm researcher ever to be selected.

This french immunologist developed Immunoscore®, a diagnostic tool that helps oncologists to predict the risk of relapse in colon cancer patients, depending on the strength of their immune response. It allows to oncologists to provide more personalized treatment options  suited to each patient’s profile.

Immunoscore® is the next step in the evolution of  therapy  for colon cancer patients. « Our team discovered that tumor aggressiveness is not the only factor that helps to determine a prognosis.  The extent  of the immune system activity plays a major role : the higher the number of immune cells in a particular distribution in the tumor tissue, the longer the life expectancy of a cancer patient, » explains Jérôme Galon.

The Immunoscore® technology utilized of digital image analysis  of tumor samples  to precisely measure infiltrating T-lymphocytes in the core tumor and at the invasive tumor margin. Analysis of more than 3,000 patient tumors has demonstrated the ability of the assay to reliably estimate patient prognosis and provide individualized medical treatment options.

This technology is also being used in the setting of translational research by enabling assessment of  patient immune profiles in the context of immunotherapy clinical trials.

Immunoscore®, a true example of bench-to-bedside translational research, is realized with the creation of HalioDx

Tumor aggressiveness is not the only factor that helps to determine a prognosis.

To enable patient access to his invention, Jérôme Galon co-founded HalioDx in 2014 and presides on it’s scientific board. Just 4 years later, HalioDx has expanded to more than 165 employees, with headquarters in France and a subsidiary HalioDx Inc in Richmond, Virginia, United States.

« We are so happy for Jérôme and his Inserm laboratory from the Cordeliers research Center in Paris to hear the news of his 2019 european inventor award for Immunoscore®. This is also very positive for for HalioDx, who makes this revolutionary invention available to patients worldwide » notes Vincent Fert, CEO of HalioDx.

HalioDx establishes strong partnerships with the pharmaceutical industry 

In addition to performing diagnostic assays, HalioDx also provides comprehensive immune profiling biomarker options as a service to biopharmaceutical companies to help them for biomarker evaluation in translational research or during their clinical trials.

These assays employ a suite of state-of-the-art technologies, including multiplex IHC, NGS, and digital pathology analysis, providing highly customized solutions fitted to the specifics needs of pharmaceutical manufacturers. This technology has been particularly useful in identification of patient response or resistance to combinations treatment with immunotherapies or CAR-T products.

Don’t miss the seminar organized by Biowin on october the 24th in Gosselies to meet HalioDx team and discover how HalioDx can partner with you to build custom of immuno-biomarker solution

 

You can register here http://events.biowin.org/fr/event/consult/14